Investigating a treatment to prevent cognitive decline in asymptomatic Alzheimer's disease.
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study
['FUNDING_R01'] · BRIGHAM AND WOMEN'S HOSPITAL · NIH-10767280
This study is looking for older adults who have early signs of Alzheimer's but aren't showing symptoms yet, to see if a treatment called solanezumab can help keep their thinking skills sharp and delay any memory problems.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BRIGHAM AND WOMEN'S HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10767280 on ClinicalTrials.gov |
What this research studies
This research focuses on an open-label extension of a previous study aimed at preventing cognitive decline in older adults who show early signs of Alzheimer's disease but are not yet symptomatic. Participants undergo screening with PET scans to identify elevated amyloid-beta levels, which are linked to Alzheimer's pathology. The study tests an immunotherapy treatment called solanezumab, which targets amyloid-beta, to see if it can delay or prevent the onset of cognitive symptoms. The research involves a large cohort of older adults, and the findings could provide valuable insights into early intervention strategies for Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults aged 65-85 who are asymptomatic but have elevated amyloid-beta levels as indicated by PET scans.
Not a fit: Patients who are already symptomatic or do not have elevated amyloid-beta levels may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly delay or prevent the onset of Alzheimer's disease in at-risk individuals.
How similar studies have performed: Previous studies targeting amyloid-beta in Alzheimer's disease have shown promise, but this specific approach in asymptomatic individuals is relatively novel.
Where this research is happening
BOSTON, UNITED STATES
- BRIGHAM AND WOMEN'S HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SPERLING, REISA A. — BRIGHAM AND WOMEN'S HOSPITAL
- Study coordinator: SPERLING, REISA A.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease